Drug Profile
A 1211212
Alternative Names: A-1211212Latest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator AbbVie
- Class Anti-inflammatories; Antineoplastics; Small molecules
- Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c-bcl-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammatory bowel diseases
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in USA (PO)
- 06 May 2017 Preclinical trials in Inflammatory bowel disease in USA (PO)
- 06 May 2017 Pharmacodynamics data from a preclinical study in Inflammatory bowel disease presented at the Digestive Disease Week (DDW-2017)